Status: Not yet recruiting
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but subsequently had a disease recurrence.
Participants needed: 30
Trial details
Phase: Phase 4Age: 18-75Biological sex: AllType: InterventionalSponsor: Viridian Therapeutics, Inc.Updated: Sep 21, 2026Locations: 8
Eligibility criteria
Must have a diagnosis of TED with associated signs and symptoms. [+7]
Must not have sight-threatening TED (eg, dysthyroid optic neuropathy). [+9]